Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Multi-Center, Parallel-Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD (Ethos)
Brief Summary: This is a randomized, double-blind, multi-center, parallel-group study to assess the efficacy and safety of PT010 relative to PT003 and PT009 on COPD exacerbations subjects with moderate to very severe COPD.


Options:
A: Arm Label: fluticasone furoate/umeclidinium bromide/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate (FF), Drug: vilanterol (VI), Drug: umeclidinium bromide (UMEC) | Arm Label: fluticasone furoate/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate (FF), Drug: vilanterol (VI) | Arm Label: umeclidinium bromide/vilanterol; Type: EXPERIMENTAL; Interventions: Drug: vilanterol (VI), Drug: umeclidinium bromide (UMEC) | Intervention Type: DRUG; Name: fluticasone furoate (FF); Assigned to Arm(s): fluticasone furoate/umeclidinium bromide/vilanterol, fluticasone furoate/vilanterol | Intervention Type: DRUG; Name: vilanterol (VI); Assigned to Arm(s): fluticasone furoate/umeclidinium bromide/vilanterol, fluticasone furoate/vilanterol, umeclidinium bromide/vilanterol | Intervention Type: DRUG; Name: umeclidinium bromide (UMEC); Assigned to Arm(s): fluticasone furoate/umeclidinium bromide/vilanterol, umeclidinium bromide/vilanterol
B: Arm Label: BGF (PT010) MDI 320/14.4/9.6 μg; Type: EXPERIMENTAL; Interventions: Drug: BGF MDI 320/14.4/9.6 μg | Arm Label: BGF (PT010) MDI 160/14.4/9.6 μg; Type: EXPERIMENTAL; Interventions: Drug: BGF MDI 160/14.4/9.6 μg | Arm Label: BFF (PT009) MDI 320/9.6 μg; Type: EXPERIMENTAL; Interventions: Drug: BFF MDI 320/9.6 μg | Arm Label: GFF (PT003) MDI 14.4/9.6 μg; Type: EXPERIMENTAL; Interventions: Drug: GFF MDI 14.4/9.6 μg | Intervention Type: DRUG; Name: BGF MDI 320/14.4/9.6 μg; Assigned to Arm(s): BGF (PT010) MDI 320/14.4/9.6 μg | Intervention Type: DRUG; Name: GFF MDI 14.4/9.6 μg; Assigned to Arm(s): GFF (PT003) MDI 14.4/9.6 μg | Intervention Type: DRUG; Name: BGF MDI 160/14.4/9.6 μg; Assigned to Arm(s): BGF (PT010) MDI 160/14.4/9.6 μg | Intervention Type: DRUG; Name: BFF MDI 320/9.6 μg; Assigned to Arm(s): BFF (PT009) MDI 320/9.6 μg
C: Arm Label: BGF MDI (PT010) 320/14.4/9.6 μg ex-actuator; Type: EXPERIMENTAL; Interventions: Drug: BGF MDI 320/14.4/9.6 μg | Arm Label: GFF MDI (PT003) 14.4/9.6 μg ex-actuator; Type: EXPERIMENTAL; Interventions: Drug: GFF MDI (PT003) 14.4/9.6 μg | Arm Label: BFF MDI (PT009) 320/9.6 μg ex-actuator; Type: EXPERIMENTAL; Interventions: Drug: BFF MDI (PT009) 320/9.6 μg | Arm Label: Symbicort; Type: ACTIVE_COMPARATOR; Interventions: Drug: Symbicort® Turbuhaler® (TBH) Inhalation Powder | Intervention Type: DRUG; Name: BGF MDI 320/14.4/9.6 μg; Assigned to Arm(s): BGF MDI (PT010) 320/14.4/9.6 μg ex-actuator | Intervention Type: DRUG; Name: GFF MDI (PT003) 14.4/9.6 μg; Assigned to Arm(s): GFF MDI (PT003) 14.4/9.6 μg ex-actuator | Intervention Type: DRUG; Name: BFF MDI (PT009) 320/9.6 μg; Assigned to Arm(s): BFF MDI (PT009) 320/9.6 μg ex-actuator | Intervention Type: DRUG; Name: Symbicort® Turbuhaler® (TBH) Inhalation Powder; Assigned to Arm(s): Symbicort
D: Arm Label: CHF 5993 + Ultibro matched placebo; Type: EXPERIMENTAL; Interventions: Drug: CHF 5993 + Ultibro matched placebo, Procedure: Central spirometry, Other: COPD assessment test, Procedure: Local laboratory Assessments, Other: Saint George's Respiratory Questionnaire, Other: EXACT-pro questionnaire | Arm Label: Ultibro + CHF 5993 matched placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ultibro + CHF 5993 matched placebo, Procedure: Central spirometry, Other: COPD assessment test, Procedure: Local laboratory Assessments, Other: Saint George's Respiratory Questionnaire, Other: EXACT-pro questionnaire | Intervention Type: DRUG; Name: CHF 5993 + Ultibro matched placebo; Assigned to Arm(s): CHF 5993 + Ultibro matched placebo | Intervention Type: DRUG; Name: Ultibro + CHF 5993 matched placebo; Assigned to Arm(s): Ultibro + CHF 5993 matched placebo | Intervention Type: PROCEDURE; Name: Central spirometry; Assigned to Arm(s): CHF 5993 + Ultibro matched placebo, Ultibro + CHF 5993 matched placebo | Intervention Type: OTHER; Name: COPD assessment test; Assigned to Arm(s): CHF 5993 + Ultibro matched placebo, Ultibro + CHF 5993 matched placebo | Intervention Type: PROCEDURE; Name: Local laboratory Assessments; Assigned to Arm(s): CHF 5993 + Ultibro matched placebo, Ultibro + CHF 5993 matched placebo | Intervention Type: OTHER; Name: Saint George's Respiratory Questionnaire; Assigned to Arm(s): CHF 5993 + Ultibro matched placebo, Ultibro + CHF 5993 matched placebo | Intervention Type: OTHER; Name: EXACT-pro questionnaire; Assigned to Arm(s): CHF 5993 + Ultibro matched placebo, Ultibro + CHF 5993 matched placebo

Answer: B